leucovorin calcium / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 424 Diseases   809 Trials   809 Trials   14393 News 


«12...146147148149150151152153154155156...235236»
  • ||||||||||  leucovorin calcium / Generic mfg.
    Clinical, Journal:  Congenital toxoplasmosis in twins: case report (Pubmed Central) -  Sep 4, 2020   
    One or both newborns may be compromised. Multidisciplinary monitoring is essential for the early detection of reactivations or progression of lesions.
  • ||||||||||  leucovorin calcium / Generic mfg., fluorouracil topical / Generic mfg., Onivyde (nanoliposomal irinotecan) / Servier, Ipsen, Takeda
    Clinical, Review, Journal, HEOR, Real-world evidence:  Comparing real-world evidence among patients with metastatic pancreatic ductal adenocarcinoma treated with liposomal irinotecan. (Pubmed Central) -  Sep 4, 2020   
    This literature review compared the clinical characteristics and outcomes of available real-world evidence (RWE) for liposomal irinotecan in combination with 5-fluorouracil (5-FU) and leucovorin (LV), a treatment regimen indicated for patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) who previously progressed on gemcitabine-based therapy...Patients analyzed by RWE studies tended to be older with significant disease progression, poor performance status, and more heavily pretreated compared with the phase III registrational trial (NAPOLI-1). Despite this, patients treated with liposomal irinotecan + 5-FU/LV therapy had similar outcomes as those in NAPOLI-1.
  • ||||||||||  leucovorin calcium / Generic mfg., fluorouracil / Generic mfg.
    [VIRTUAL] Current therapy landscape for pancreatic cancer patients in a network of private oncologists (Abstract video presentations) -  Sep 3, 2020 - Abstract #DGHO2020DGHO_2015;    
    Especially in younger pts the proportion of platinum-based treatment protocols increased considerably over time. Referring to new study data on maintenance targeted therapy after platinum-based chemotherapy e.g. olaparib in pts with BRCA germline mutations this development could increase the number of pts qualifying for this new concept.
  • ||||||||||  leucovorin calcium / Generic mfg., fluorouracil / Generic mfg.
    [VIRTUAL] Current therapy landscape for pancreatic cancer patients in a network of private oncologists (Abstract video presentations) -  Sep 3, 2020 - Abstract #DGHO2020DGHO_1298;    
    Especially in younger pts the proportion of platinum-based treatment protocols increased considerably over time. Referring to new study data on maintenance targeted therapy after platinum-based chemotherapy e.g. olaparib in pts with BRCA germline mutations this development could increase the number of pts qualifying for this new concept.
  • ||||||||||  leucovorin calcium / Generic mfg., fluorouracil / Generic mfg.
    [VIRTUAL] Current therapy landscape for pancreatic cancer patients in a network of private oncologists (Abstract video presentations) -  Sep 3, 2020 - Abstract #DGHO2020DGHO_488;    
    Especially in younger pts the proportion of platinum-based treatment protocols increased considerably over time. Referring to new study data on maintenance targeted therapy after platinum-based chemotherapy e.g. olaparib in pts with BRCA germline mutations this development could increase the number of pts qualifying for this new concept.
  • ||||||||||  leucovorin calcium / Generic mfg., fluorouracil / Generic mfg.
    Review, Journal:  Optimizing Therapies in the Perioperative Management of Gastric Cancer. (Pubmed Central) -  Aug 27, 2020   
    However, doublet fluoropyrimidine/platinum combination is a reasonable alternative if triplet regimen cannot be given. At present, there are no approved targeted or immunotherapy agents in perioperative setting; however, there are a number of ongoing trials designed to examine the efficacy of targeted therapy and checkpoint inhibitors in various combinations with systemic therapy in perioperative setting.
  • ||||||||||  leucovorin calcium / Generic mfg., methotrexate / Generic mfg.
    Clinical, Journal:  Experience with ambulatory high-dose methotrexate administration as CNS prophylaxis in patients with non-Hodgkin lymphoma. (Pubmed Central) -  Aug 27, 2020   
    At present, there are no approved targeted or immunotherapy agents in perioperative setting; however, there are a number of ongoing trials designed to examine the efficacy of targeted therapy and checkpoint inhibitors in various combinations with systemic therapy in perioperative setting. Ambulatory administration of high-dose methotrexate as CNS prophylaxis is safe and feasible following the described approach, allowing us to optimize healthcare resources.
  • ||||||||||  leucovorin calcium / Generic mfg., methotrexate / Generic mfg., doxorubicin hydrochloride / Generic mfg.
    Journal:  Grand Round: Reversible impaired methotrexate clearance after platinum-based chemotherapy for osteosarcoma. (Pubmed Central) -  Aug 27, 2020   
    During the first cycle, severe MTX toxicity was observed with increased MTX serum levels and delayed MTX clearance requiring rescue treatment with intensified leucovorin...Prior treatment with cisplatin may well have been responsible for decreased MTX clearance and combination treatment should be used with adequate monitoring of MTX levels. Other factors that may have contributed, such as urine alkalization, gene polymorphisms, and other drug-drug interactions are discussed.
  • ||||||||||  Modufolin (arfolitixorin) / Isofol Medical, Solasia
    Enrollment open, Trial initiation date:  Modelle 001, TS-inhibition in Colorectal Liver Metastases Comparing Arfolitixorin and Calciumfolinate (clinicaltrials.gov) -  Aug 27, 2020   
    P2,  N=30, Recruiting, 
    We believe that 5-flourouracil+leucovorin or capecitabine regimens should be recommended for these older high-risk patients who could receive adjuvant chemotherapy regardless of age. Not yet recruiting --> Recruiting | Initiation date: Oct 2019 --> Feb 2020
  • ||||||||||  leucovorin calcium / Generic mfg., fluorouracil / Generic mfg.
    [VIRTUAL] RARE CASE OF OESOPHAGEAL CANCER AND TREATMENT RELATED COMPLICATION (Foyer) -  Aug 26, 2020 - Abstract #SIOP2020SIOP_1167;    
    Despite dose reduction and close monitoring, patient succumbed to cardiac events. Due to the rarity of such tumours in children, they need to be cared for in combination with adult oncologists for better understanding of these tumours and complications of their treatment.
  • ||||||||||  leucovorin calcium / Generic mfg., methotrexate / Generic mfg.
    [VIRTUAL] TOXICITY PROFILE AND CLEARANCE OF HIGH DOSE METHOTREXATE IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA - EXPERIENCE FROM A TERTIARY CANCER CENTRE OF INDIA (Foyer) -  Aug 26, 2020 - Abstract #SIOP2020SIOP_891;    
    Significant drug interactions included co-administration of oral voriconazole in 8.7%(n=36) infusions resulting in skin rash, prolonged hepatic dysfunction, prolonged MTX clearance and oral levetiracetam in 3.4%(n=16) infusions resulting in prolonged MTX clearance. Conclusions HDMTX can be safely administered in children with ALL by implementing strict hydration protocol, alkalinisation, administration by trained staff nurse, drug level monitoring at 54-hour time point and adjusted dosing of leucovorin rescue with serious toxicities limited to less than 10% of the infusions.
  • ||||||||||  leucovorin calcium / Generic mfg., methotrexate / Generic mfg.
    [VIRTUAL] SAFETY ANALYSIS OF HIGH-DOSE METHOTREXATE IN PEDIATRIC PATIENTS WITH NON-HODGKIN LYMPHOMAS (Hall 6) -  Aug 26, 2020 - Abstract #SIOP2020SIOP_565;    
    Conclusions More than half of pediatric patients with NHL in a US tertiary care children’s hospital experienced at least one episode of delayed HDMTX clearance, and some develop serious toxicities such as Grade 3 or 4 mucositis. These results may be used to inform safe HDMTX approaches in Sub-Saharan Africa.
  • ||||||||||  oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
    Trial completion date, Trial primary completion date, Metastases:  Phase 3 Study of FOLFIRINOX (mFFX) +/- SBRT in Locally Advanced Pancreatic Cancer (clinicaltrials.gov) -  Aug 25, 2020   
    P3,  N=27, Active, not recruiting, 
    Not yet recruiting --> Recruiting Trial completion date: Sep 2021 --> Sep 2022 | Trial primary completion date: Sep 2020 --> Sep 2021
  • ||||||||||  leucovorin calcium / Generic mfg.
    Trial completion date, Trial primary completion date:  Treatment of Social and Language Deficits With Leucovorin for Young Children With Autism (clinicaltrials.gov) -  Aug 24, 2020   
    P2,  N=80, Not yet recruiting, 
    Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Dec 2021 --> Dec 2022 Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Dec 2021 --> Dec 2022
  • ||||||||||  leucovorin calcium / Generic mfg., methotrexate / Generic mfg.
    Journal:  Corneal Epithelial Toxicity after Intravitreal Methotrexate Injection for Vitreoretinal Lymphoma: Clinical and In Vitro Studies. (Pubmed Central) -  Aug 24, 2020   
    The addition of folinic acid significantly protected the cells from the methotrexate-induced toxicity. Hence, our results suggest that care should be taken to minimize the contact of methotrexate with corneal epithelium during injection, and folic or folinic acid supplementation might be beneficial for preventing corneal complications in patients undergoing intravitreal methotrexate injections.
  • ||||||||||  Trial completion date, Trial initiation date, Trial primary completion date, Metastases:  Triplet Combination of Cytotoxics as First-line Treatment for Metastatic Gastric Cancer (clinicaltrials.gov) -  Aug 23, 2020   
    P3,  N=388, Not yet recruiting, 
    Hence, our results suggest that care should be taken to minimize the contact of methotrexate with corneal epithelium during injection, and folic or folinic acid supplementation might be beneficial for preventing corneal complications in patients undergoing intravitreal methotrexate injections. Trial completion date: Jun 2024 --> Sep 2024 | Initiation date: Jun 2020 --> Sep 2020 | Trial primary completion date: Jun 2023 --> Sep 2023
  • ||||||||||  leucovorin calcium / Generic mfg., fluorouracil / Generic mfg., irinotecan / Generic mfg.
    [VIRTUAL] Recurrent transient dysarthria due to FOLFIRINOX () -  Aug 19, 2020 - Abstract #AVAHO2020AVAHO_54;    
    Introduction:FOLFIRINOX(fluorouracil, leucovorin, irinotecan and oxaliplatin) has increased survival rates for pancreatic cancer, but has adverse effects of febrile neutropenia, thrombocytopenia, and neuropathy...Upon ED evaluation, she was given methylprednisolone and diphenhydramine with complete resolution of symptoms.At 3rd cycle, intravenous atropine was given prior to irinotecan infusion...Atropine is known to work well in preventing acute cholinergic syndrome but has shown mixed results in treating dysarthria. It is reassuring that irinotecan-induced dysarthria is self-limiting, but an increased awareness among physicians is needed so that this adverse effect is not misdiagnosed as a stroke.
  • ||||||||||  Stivarga (regorafenib) / Bayer
    Trial completion date, Combination therapy, Metastases:  Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer (clinicaltrials.gov) -  Aug 18, 2020   
    P2,  N=181, Active, not recruiting, 
    It is reassuring that irinotecan-induced dysarthria is self-limiting, but an increased awareness among physicians is needed so that this adverse effect is not misdiagnosed as a stroke. Trial completion date: Jul 2020 --> Oct 2020